Skip to content

EHC

Current
Price
$133.61
Discount category
Close to intrinsic value
Intrinsic value source
AI estimate
Next earnings
Jan 28, 2027
Next earnings is estimate
Yes
Company name
Encompass Health
Sector
Inpatient rehabilitation hospitals
About
Encompass Health Corporation (EHC) is based in Birmingham, Alabama. It is the largest owner and operator of inpatient rehabilitation hospitals in the United States, with 179 hospitals in 39 states and Puerto Rico. The hospitals treat patients who recover from a stroke, a brain or spinal cord injury, a hip fracture or another major illness or injury. Many hospitals are joint ventures with acute care hospitals, which own part of them. Medicare gave 65.7% and Medicare Advantage 16.1% of net operating revenues in the nine months to September 30, 2026. Net operating revenues were $5.9 billion in 2025. The common stock trades on the NYSE in US dollars. Encompass Health files 10-K and 10-Q reports.
Thesis
The market pays close to the AI estimate for Encompass Health because steady growth in patients and new hospitals is balanced by Medicare rules that can slow payments. In Q3 2026, discharges rose 5.7%, net patient revenue per discharge rose 4.0% and adjusted EBITDA rose 15.5%. From January 1, 2027, the Medicare review choice demonstration covers 108 of its hospitals, about 63% of its Medicare claims, so many more claims need a review before or after payment. For the value to rise, three things must be true. The company must reach its 2026 guidance of adjusted EPS of $6.23 to $6.37 and guide more growth for 2027. The wider claim reviews must not cut admissions or delay cash. New hospitals and beds must fill as planned, after capital spending of $920 million to $995 million in 2026. The Q4 2026 report with 2027 guidance, expected in late January 2027, is the next test. If Medicare cuts rates or Medicare Advantage plans send fewer patients, earnings can grow more slowly.
Valuation
The intrinsic value for Encompass Health is an AI estimate from November 14, 2026. It is not an analyst's value. An AI research agent calculated it from the filings of Encompass Health with the SEC. The method is a multiple of 2027 adjusted earnings per share from continuing operations. Adjusted earnings are after interest and after the share of the partners in joint venture hospitals, so the estimate makes no separate adjustment for debt or for those partners. The Q4 2025 release (8-K, February 5, 2026) gives 2025 adjusted EPS of $5.45. The Q3 2026 release (8-K, October 28, 2026) gives Q3 net operating revenue of $1,609.5 million, up 8.9%, adjusted EBITDA of $346.6 million, adjusted EPS of $1.52 and 99.7 million diluted weighted shares. It raises 2026 guidance to net operating revenue of $6,450 million to $6,500 million, adjusted EBITDA of $1,395 million to $1,415 million and adjusted EPS of $6.23 to $6.37, and the company confirmed this guidance on November 6, 2026 (8-K). The Form 10-Q for the quarter ended September 30, 2026 gives long-term debt of $2,599.1 million, including finance leases, and cash of $76.2 million. It says that Medicare gave 65.7% and Medicare Advantage 16.1% of net operating revenues in nine months. The cover of the 10-Q gives 98,123,613 shares at October 22, 2026. The 2027 adjusted EPS and the multiples are assumptions. The low case assumes $6.40, because wider Medicare claim reviews and Medicare Advantage plans limit admissions, at 16 times. It gives $102.40 per share. The base case assumes $7.00, from new hospitals and beds, at 20 times. It gives $140.00 per share. The high case assumes $7.60, from faster growth in discharges and share buybacks, at 23 times. It gives $174.80 per share. The estimate assumes weights of 25%, 50% and 25%. The weighted intrinsic value is $139.30 per share. Encompass Health is the largest operator of inpatient rehabilitation hospitals in the United States, and its scale, its joint ventures with acute care hospitals and the licenses that many states require make new competition slow, but Medicare sets most of its prices and can change its rules. As of Nov 14, 2026.
Risks
Medicare gave 65.7% of net operating revenues in the nine months to September 30, 2026. A cut in Medicare rates or new coverage rules can lower revenue. From January 1, 2027, the review choice demonstration covers 108 of its hospitals, about 63% of its Medicare claims. More reviews can delay payments and lead to more denied claims. Medicare Advantage gave 16.1% of net operating revenues in nine months of 2026, and these plans can limit the access of patients to inpatient rehabilitation. The company spends much on new hospitals and beds: $617 million of capital expenditures in nine months of 2026, and about $535 million more to complete the projects under construction. New hospitals that fill slowly lower returns. Salaries and benefits were $2,479.1 million, or 52% of net operating revenues, in nine months of 2026. A shortage of nurses and therapists can raise costs.
Balance sheet
Cash: $76M Debt: $2.6B Net debt: $2.6B EBITDA, last 12 months: $1.4B Net debt / EBITDA: 1.9× (low) Undrawn credit line: $871M, to March 2031 Debt due within 12 months: $48M At September 30, 2026, Encompass Health had cash and cash equivalents of $76.2 million. Debt was $2,630.0 million at face value, including finance lease obligations of $274.9 million and $75.0 million drawn under the revolving credit facility. The senior notes are due in 2028, 2030, 2031 and 2034, and the next large maturity is $400 million of 4.50% notes in 2028. About $871 million was available under the revolving credit facility, which runs to March 9, 2031. Partners in joint venture hospitals held noncontrolling interests of $821.4 million. Encompass Health shareholders' equity was $2,681.2 million. As of Sep 30, 2026.
Checkpoints
Jan 28, 2027 (estimate): Q4 2026 results and 2027 guidance. Pending. Watch: 2026 adjusted EPS is in the guided range of $6.23 to $6.37 and 2027 guidance shows more growth, and this passes; flat or lower 2027 guidance fails. Apr 2027 (estimate): Q1 2027 results: wider Medicare claim reviews. Pending. Watch: Discharges keep growing and denied claims do not rise after the review choice demonstration widens on January 1, 2027, and this passes; lower admissions or more denials fail.
Recent events
Nov 6, 2026: Floods closed the 90-bed Sea Pines Rehabilitation Hospital in Melbourne, Florida, a joint venture with Holmes Regional Medical Center, for an indefinite time. Encompass Health confirmed its 2026 guidance and will leave the closure costs and insurance proceeds out of its non-GAAP results. Oct 28, 2026: Encompass Health reported Q3 2026 results. Net operating revenue rose 8.9% to $1,609.5 million, adjusted EBITDA rose 15.5% to $346.6 million and adjusted EPS was $1.52. It raised 2026 guidance to adjusted EBITDA of $1,395 million to $1,415 million and adjusted EPS of $6.23 to $6.37. Sep 25, 2026: CMS said that the review choice demonstration for inpatient rehabilitation facilities will cover all facilities that bill to a certain Medicare contractor from January 1, 2027. This brings 108 hospitals of Encompass Health, about 63% of its Medicare claims, into the demonstration. Aug 13, 2026: Encompass Health sold $100 million more of its 5.875% senior notes due 2034 at 98.75% of principal, and it used the money to repay part of its revolving credit facility. Jul 30, 2026: CMS issued the final rule for Medicare payments to inpatient rehabilitation facilities for fiscal 2027, with a net market basket increase of 2.3% from October 1, 2026. Jul 23, 2026: The Board raised the quarterly dividend from $0.19 to $0.21 per share and increased the share repurchase authorization to $1.0 billion. May 29, 2026: Encompass Health sold $500 million of 5.875% senior notes due 2034, and it used the money to redeem $400 million of its 4.50% senior notes due 2028 and to repay $100 million under its revolving credit facility. Mar 9, 2026: Encompass Health signed a new credit agreement that matures on March 9, 2031, and repaid the credit agreement of 2022. Feb 5, 2026: Encompass Health reported 2025 results with revenue up 10.5% and adjusted EBITDA up 14.9%, and adjusted EPS of $5.45. It added 517 beds in 2025 and guided 2026 adjusted EPS of $5.81 to $6.10.
See changes